{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T15:56:19Z","timestamp":1772726179610,"version":"3.50.1"},"reference-count":38,"publisher":"SLACK, Inc.","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Psychosoc Nurs Ment Health Serv"],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:p>Similar to benzodiazepines, gabapentinoids are used to reduce central nervous system hyperexcitability. Unlike benzodiazepines, gabapentinoids are not approved by the U.S. Food and Drug Administration for the treatment of psychiatric disorders, even in disorders characterized by excitatory-inhibitory imbalances in neuronal circuits. The current article explores the indications, concerns, trends in prescribing, and clinical guidance offered to clinicians for making safe decisions regarding use of gabapentinoids.<\/jats:p>","DOI":"10.3928\/02793695-20260205-01","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T13:58:41Z","timestamp":1772719121000},"page":"7-10","source":"Crossref","is-referenced-by-count":0,"title":["Concerns About Gabapentinoids in Psychiatric Practice"],"prefix":"10.3928","volume":"64","author":[{"given":"Karan","family":"Kverno","sequence":"first","affiliation":[{"name":"Georgetown University Berkley School of Nursing, Washington, D.C."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2308","reference":[{"key":"e_1_3_1_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.18372"},{"key":"e_1_3_1_3_1","doi-asserted-by":"publisher","unstructured":"Attar A. A. Halabi M. H. Barnawi E. T. Sindi G. K. Altayeb A. A. Fadel F. T. Alsubhi L. H. Alsamiri G. Y. & Alsabban A. S. (2025). Evaluating the efficacy and safety of duloxetine and gabapentin in managing diabetic neuropathy: A systematic review and meta-analysis. British Journal of Pain. Advance online publication. 10.1177\/20494637251365690 PMID:40786125","DOI":"10.1177\/20494637251365690"},{"key":"e_1_3_1_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/1556-4029.15500"},{"key":"e_1_3_1_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01670-3"},{"key":"e_1_3_1_6_1","doi-asserted-by":"publisher","DOI":"10.7326\/ANNALS-24-00636"},{"key":"e_1_3_1_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2025.104904"},{"key":"e_1_3_1_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.70074"},{"key":"e_1_3_1_9_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.202000338"},{"key":"e_1_3_1_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.24140"},{"key":"e_1_3_1_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/ppe.13086PMID:38773683"},{"key":"e_1_3_1_12_1","unstructured":"Drug Enforcement Administration. (2025 March). Gabapentin (trade name: Neurontin\u00ae). https:\/\/www.deadiversion.usdoj.gov\/drug_chem_info\/gabapentin.pdf"},{"key":"e_1_3_1_13_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.pn.2023.11.11.29"},{"key":"e_1_3_1_14_1","doi-asserted-by":"publisher","unstructured":"Eghrari N. B. Yazji I. H. Yavari B. Van Acker G. M. & Kim C. H. (2025). Risk of dementia following gabapentin prescription in chronic low back pain patients. Regional Anesthesia and Pain Medicine. Advance online publication. 10.1136\/rapm-2025-106577 PMID:40639955","DOI":"10.1136\/rapm-2025-106577"},{"key":"e_1_3_1_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109713"},{"key":"e_1_3_1_16_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000213786"},{"key":"e_1_3_1_17_1","author":"Institute for Healthcare Improvement","unstructured":"Institute for Healthcare Improvement. (n.d.). Age-friendly health systems. https:\/\/www.ihi.org\/partner\/initiatives\/age-friendly-health-systems","journal-title":"Age-friendly health systems"},{"key":"e_1_3_1_18_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200825030-00002"},{"key":"e_1_3_1_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14655"},{"key":"e_1_3_1_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.13659"},{"key":"e_1_3_1_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(04)00792-6"},{"issue":"7","key":"e_1_3_1_22_1","first-page":"55","article-title":"Psychiatric uses of gabapentin","volume":"19","author":"Martin J. C.","year":"2022","unstructured":"Martin, J. C., & Gainer, D. (2022). Psychiatric uses of gabapentin. Innovations in Clinical Neuroscience, 19(7\u20139), 55\u201360. PMID:36204172","journal-title":"Innovations in Clinical Neuroscience"},{"key":"e_1_3_1_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-020-00189-x"},{"key":"e_1_3_1_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15532"},{"key":"e_1_3_1_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.19482"},{"key":"e_1_3_1_26_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2020.26.3.246"},{"key":"e_1_3_1_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/1178221818801311"},{"key":"e_1_3_1_28_1","author":"Public Citizen","year":"2022","unstructured":"Public Citizen. (2022, February 9). Petition to the DEA and FDA to classify the drug gabapentin as a schedule V controlled substance. https:\/\/www.citizen.org\/article\/petition-to-the-deaand-fda-to-classify-the-drug-gabapentin-asa-schedule-v-controlled-substance\/","journal-title":"Petition to the DEA and FDA to classify the drug gabapentin as a schedule V controlled substance"},{"key":"e_1_3_1_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/acer.14408"},{"key":"e_1_3_1_30_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2017.1750101"},{"key":"e_1_3_1_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/CORR.0000000000003381"},{"key":"e_1_3_1_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/papr.13165"},{"key":"e_1_3_1_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-019-0426-0"},{"key":"e_1_3_1_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13844"},{"key":"e_1_3_1_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-023-01066-w"},{"key":"e_1_3_1_36_1","unstructured":"U.S. Food and Drug Administration. (2019). FDA warns about serious breathing problems with seizure and nerve pain medications gabapentin (Neurontin Gralise Horizant) and pregabalin (Lyrica Lyrica CR) when used with CNS depressants or in patients with lung problems. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-neurontin"},{"key":"e_1_3_1_37_1","author":"U.S. Food and Drug Administration","year":"2020","unstructured":"U.S. Food and Drug Administration. (2020). Horizant: Highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/022399s011lbl.pdf","journal-title":"Horizant: Highlights of prescribing information"},{"key":"e_1_3_1_38_1","author":"U.S. Food and Drug Administration","year":"2025","unstructured":"U.S. Food and Drug Administration. (2025). Neurontin: Highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/020235s079,020882s060,021129s059lbl.pdf","journal-title":"Neurontin: Highlights of prescribing information"},{"key":"e_1_3_1_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/07317115.2024.2379974"}],"container-title":["Journal of Psychosocial Nursing and Mental Health Services"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T14:54:16Z","timestamp":1772722456000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/02793695-20260205-01"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,1]]}},"alternative-id":["10.3928\/02793695-20260205-01"],"URL":"https:\/\/doi.org\/10.3928\/02793695-20260205-01","relation":{},"ISSN":["0279-3695","1938-2413"],"issn-type":[{"value":"0279-3695","type":"print"},{"value":"1938-2413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]}}}